Skip to main content
Graduate School of Biomedical Sciences

Recent Publications from the Kuliopulos Lab

Rana R, Shearer AM, Fletcher EK, Nguyen N, Guha S, Cox DH, Abdelmalek M, Wang Y, Baleja JD, Covic L, Kuliopulos A. 2019. PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease. Mol Metab. 29:99-113. Abstract

Bliden K, Chaudhary R, Kuliopulos A, Tran H, Taheri H, Tehrani B, Rosenblatt A, Navarese E, Tantry US, Gurbel P. 2019. Effects of Vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono-and dual-antiplatelet therapy. J Thromb Haemost. doi: 10.1111/jth.14616. Abstract

Kimmelstiel C, Stevenson R, Nguyen N, Van Doren L, Zhang P, Perkins J, Kapur NK, Weintraub A, Castaneda V, Kuliopulos A, Covic L. 2019. Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel. Thromb Res. 177: 59-69. Abstract

Michael ES, Covic L, Kuliopulos A. 2019. TAAR1 promotes anti-diabetic signaling in insulin-secreting cells. J Biol Chem. Epub ahead of print. Abstract

Barr TP, Garzia C, Guha S, Fletcher EK, Nguyen N, Wieschhaus AJ, Ferrer L, Covic L, Kuliopulos A. 2018. PAR2 pepducin-based suppression of inflammation and itch in atopic dermatitis models. J Invest Dermatol. Epub ahead of print. Abstract

Covic L, Kuliopulos A. 2018. Protease-activated receptor 1 as therapeutic target in breast, lung, and ovarian cancer: Pepducin approach. Int J Mol Sci. 19: E2237. Abstract

Rana R, Huang T, Koukos G, Fletcher EK, Turner SE, Shearer A, Gurbel PA, Rade JJ, Kimmelstiel CD, Bliden KP, Covic L, Kuliopulos A. 2018. Noncanonical matrix metalloprotease 1-protease-activated receptor 1 signaling drives progression of atherosclerosis. Arterioscler Thromb Vasc Biol. Epub ahead of print.  Abstract

Shearer AM, Rana R, Austin K, Baleja JD, Nguyen N, Bohm A, Covic L, Kuliopulos A. 2016. Targeting liver fibrosis with a cell-penetrating PAR2 pepducin. J Biol Chem. 291: 23188-23198. Abstract

Wieser V, Adolph TE, Enrich B, Kuliopulos A, Kaser A, Tilg H, Kaneider NC. 2016. Reversal of murine alcoholic steatohepatitis by pepducin-based functional blockade of interleukin-8 receptors. Gut Epub ahead of print.  Abstract

Gurbel PA, Bliden KP, Turner SE, Tantry US, Gesheff MG, Barr TP, Covic L, Kuliopulos A. 2015. Cell-penetrating pepducin therapy targeting PAR1 in subjects with coronary artery disease. Arterioscler Thromb Vasc Biol. 36: 189-197.  Abstract

Zhang P, Covic L, Kuliopulos A. 2015. Pepducins and other lipidated peptides as mechanistic probes and therapeutics. Methods Mol Biol. 1324: 191-203.  Abstract

Yang E, Cisowski J, Nguyen N, O'Callaghan K, Xu J, Agarwal A, Kuliopulos A, Covic L. 2015. Dysregulated protease activated receptor 1 (PAR1) promotes metastatic phenotype in breast cancer through HMGA2. Oncogene 35: 1529-1540. Abstract

Zhang P, Leger AJ, Baleja JD, Rana R, Corlin T, Nguyen N, Koukos G, Bohm A, Covic L, Kuliopulos A. 2015. Allosteric activation of a G protein coupled receptor with cell-penetrating receptor mimetics. J Biol Chem. 290: 15785-15798. Abstract

Gurbel PA, Kuliopulos A, Tantry US. 2015. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol.35: 500-512 . Abstract

Foley CJ, Kuliopulos A. 2014. Mouse matrix metalloprotease-1a (Mmp1a) gives new insight Into MMP function. J Cell Physiol. 229: 1875-1880. Abstract

Austin KM, Nguyen N, Javid G, Covic L, Kuliopulos A. 2013. Non-canonical MMP1-PAR1 signaling triggers vascular smooth muscle cell de-differentiation and arterial stenosis. J Biol Chem. 288: 23105-13115. Abstract

Foley CJ, Fanjul-Fernández M, Bohm A, Nguyen N, Agarwal A, Austin K, Koukos G, Covic L, López-Otín C, Kuliopulos A. 2013. Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis. Oncogene 33: 2264-2272. Abstract

Michael ES, Kuliopulos A, Covic L, Steer ML, Perides G. 2013. Pharmacological inhibition of PAR2 with the pepducin P2pal-18S protects mice against acute experimental biliary pancreatitis. Am J Physiol Gastrointest Liver Physiol. 304: G516-G526. Abstract

Kaimal R, Aljumaily R, Tressel SL, Pradhan RV, Covic L, Kuliopulos A, Zarwan C, Kim YB, Sharifi S, Agarwal A. 2013. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis and tumor growth in ovarian cancer. Cancer Res. 73: 2457-2467. Abstract

Austin KM, Covic L, Kuliopulos A. 2013. Matrix metalloproteases and PAR1 activation. Blood. 121: 431-439. Abstract

Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O'Callaghan K, Cox DH, Bohm A, Baleja JD, Covic L, Kuliopulos A. 2012. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 126: 83091. Abstract

Foley CJ, Luo C, O’Callaghan K, Hinds P, Covic L, Kuliopulos A. 2012. Matrix metalloprotease-1a promotes tumorigenesis and metastasis. J Biol Chem. 287: 24330-24338. Abstract

O'Callaghan K, Kuliopulos A, Covic L. 2012. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem. 287: 12787-12796. Abstract

O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L. 2012. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood. 119: 1717-1725. Abstract